The pharma sector is in upheaval, with massive deals making weekly headlines and companies taking evasive action to pre-empt the advances of predators. But will separating drugs businesses from consumer healthcare divisions really reap dividends for shareholders? Owain Bennallack takes a look at GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and Reckitt Benckiser (LSE: RB)…
https://youtu.be/4kBIedPOvFM